4.6 Article

Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2

Journal

PHARMACEUTICALS
Volume 15, Issue 4, Pages -

Publisher

MDPI
DOI: 10.3390/ph15040396

Keywords

COVID-19; ion channel; drug repurposing; antiviral drug; channel blocker

Funding

  1. Israeli Science Foundation [948/19]
  2. Israeli Science Ministry [66257]

Ask authors/readers for more resources

This study demonstrates the potential of targeting viral ion channels as a treatment strategy to enhance and complement our antiviral arsenal against COVID-19. In cell-based experiments, several ion channel blockers exhibited antiviral activity, and there was synergism between certain blockers. These findings are significant for further pandemic control and development of treatment options.
SARS-CoV-2 is the etiological agent COVID-19, one of the most impactful health crises afflicting humanity in recent decades. While research advances have yielded several treatment and prevention options, the pandemic is slow to abate, necessitating an expansion of our treatment arsenal. As a member of the coronaviridae, SARS-CoV-2 contains several ion channels, of which E and 3a are the best characterized. Since ion channels as a family are excellent drug targets, we sought to inhibit both viroporins as a means to curb infectivity. In a previous targeted study, we identified several blockers to each channel from an extensive drug repurposing library. Herein, we examined the ability of said compounds on the whole virus in cellulo. Gratifyingly, many of the blockers exhibited antiviral activity in a stringent assay examining protection from viral-driven death. In particular, darapladib and flumatinib, both 3a blockers, displayed potent antiviral activity. Furthermore, appreciable synergism between flumatinib and several E blockers was identified in a concentration regime in which the compounds are present in human plasma following oral administration. Taken together, targeting ion channels represents a promising approach to both augment and complement our antiviral arsenal against COVID-19.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available